/

Sociétés

Am

Non vérifié

Amphista Therapeutics

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologiePublicité/Marketing/Médias/Communication

14 communiqués de presse

Voir tous les communiqués de presse

18/03/2026

Biotechnologie

Annonces Économiques

Publicité/Marketing/Médias/Communication

Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883

Source

Amphista Therapeutics

Émetteur

1.00

0

26/02/2026

Biotechnologie

Annonces Économiques

Publicité/Marketing/Médias/Communication

Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic

Source

Amphista Therapeutics

Émetteur

1.00

0

07/12/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Source

Amphista Therapeutics

Émetteur

1.00

0

25/11/2025

Biotechnologie

Annonces Économiques

Publicité/Marketing/Médias/Communication

Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update

Source

Amphista Therapeutics

Émetteur

1.00

0

28/10/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025

Source

Amphista Therapeutics

Émetteur

1.00

0

27/10/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications

Source

Amphista Therapeutics

Émetteur

1.00

0

23/10/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development

Source

Amphista Therapeutics

Émetteur

1.00

0

15/10/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia

Source

Amphista Therapeutics

Émetteur

1.00

0

23/09/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Annonces Économiques

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22

Source

Amphista Therapeutics

Émetteur

1.00

0

17/09/2025

Biotechnologie

Publicité/Marketing/Médias/Communication

Amphista Therapeutics discloses first details of its SMARCA2 degrader program

Source

Amphista Therapeutics

Émetteur

1.00

0

Followers

0

Compatibilité

0